Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Rating of “Moderate Buy” by Analysts

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $87.3750.

Several research analysts have recently commented on KNSA shares. Wells Fargo & Company lifted their price objective on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Canaccord Genuity Group boosted their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Finally, The Goldman Sachs Group raised their target price on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, July 30th.

Kiniksa Pharmaceuticals International Stock Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $77.91 on Monday. Kiniksa Pharmaceuticals International has a 52-week low of $35.12 and a 52-week high of $82.94. The company has a fifty day moving average of $71.98 and a 200-day moving average of $57.44. The stock has a market capitalization of $6.08 billion, a price-to-earnings ratio of 80.32 and a beta of 0.09.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. On average, equities research analysts forecast that Kiniksa Pharmaceuticals International will post 1.37 earnings per share for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 4,600 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the transaction, the chief accounting officer owned 29,062 shares of the company’s stock, valued at $2,333,678.60. This represents a 13.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the sale, the director owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. This trade represents a 23.94% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 51.98% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System increased its position in shares of Kiniksa Pharmaceuticals International by 6,384.0% during the second quarter. California State Teachers Retirement System now owns 2,721,648 shares of the company’s stock valued at $174,049,000 after buying an additional 2,679,673 shares during the period. Qube Research & Technologies Ltd lifted its holdings in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after buying an additional 653,236 shares during the period. Rubric Capital Management LP boosted its position in Kiniksa Pharmaceuticals International by 15.6% during the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after acquiring an additional 526,567 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Kiniksa Pharmaceuticals International by 220.9% during the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after acquiring an additional 506,576 shares during the period. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 213.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after acquiring an additional 447,536 shares during the period. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.